Physician profile
Amy M Becker
NPI 1124037643
$77,341.58
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,201 · 2020: $1,187 · 2021: $14K · 2022: $14K · 2023: $29K · 2024: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Consulting Fee: $14K · Travel and Lodging: $5,507 · Food and Beverage: $1,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,988.00 |
| Consulting Fee | $14,400.00 |
| Travel and Lodging | $5,506.59 |
| Food and Beverage | $1,166.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $76,315.13 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $457.28 | 2019-2024 | Ultomiris |
| Glaxosmithkline, LLC. | $146.38 | 2021-2023 | Benlysta, Jesduvroq |
| Aurinia Pharma U.S., INC. | $119.13 | 2021-2024 | Lupkynis |
| Ultragenyx Pharmaceutical INC. | $80.42 | 2019-2021 | |
| Amicus Therapeutics, INC. | $68.92 | 2019-2023 | |
| Novo Nordisk INC | $35.78 | 2023 | |
| Alnylam Pharmaceuticals INC. | $28.61 | 2023 | Oxlumo |
| Kyowa Kirin, INC. | $25.85 | 2024 | Crysvita |
| Spacelabs Healthcare INC | $21.66 | 2019 | |
| Silvergate Pharmaceuticals, INC. | $18.05 | 2019 | |
| Tolmar, INC. | $13.33 | 2024 | |
| Azurity Pharmaceuticals, INC. | $11.04 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Becker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.